Univariate analysis of clinical characteristic influence on recurrence in 219 patients with bladder cancer.

<p>Univariate analysis of clinical characteristic influence on recurrence in 219 patients with bladder cancer.</p

Analysis of relative XPF and XPC mRNA levels in bladder cancer tissue with different smoking status.

<p>The expressions of XPF and XPC in 79 the bladder cancer of 4 smoking subgroups. The coarse solid line represents the mean CT value and the error bars represents the standard error.</p

Cox multivariate regression analysis of potential recurrence predictive factors in patients with bladder cancer.

<p>Cox multivariate regression analysis of potential recurrence predictive factors in patients with bladder cancer.</p

Expression of XPF and XPC bladder cancer recurrence.

<p>Kaplan-Meier Curves using log rank tests for the recurrence of bladder cancer in patients. (a) The recurrence of bladder cancer in patients with XPF(−) and XPF(+); (b) The recurrence of bladder cancer in patients with XPC(−) and XPC(+); (c) The recurrence of bladder cancer in patients with XPF (−) combined with XPC(−) and XPF(+) combined with XPC(+), simultaneity; (d) The recurrence of bladder cancer in patients with never smoked and ever smoked. <i>Cum, cumulative</i>.</p

The RNA expressions of nine NER genes in bladder cancer tissues of three subgroups.

<p>NER genes transcript were detected by real-time quantitative RT-PCR in bladder cancers of three subgroups: Non-recurrence Group, patients who didn't have a recurrence in 2 years; Recurrence Group, patients who had a recurrence within 2 years; Dead Group, patients who were dead after the surgery within two years. The fold change was normalized against GAPDH and then all genes compared with the expressions of XPC in the Recurrence Group(+signal). *, P<0.01 compared with the.Non-recurrence Group.</p

The associations of attenuated XPF/XPC expression with tumor grade and the patients' smoking status in 219 patients with bladder cancer.

<p>Note P^a value is the comparison between the group of low-grade papillary carcinoma and the group of papillary neoplasm of low malignant potential; P^b value is the comparison between the group of high-grade papillary carcinoma and the group of papillary neoplasm of low malignant potential; P^c value is the comparison between the group of high-grade papillary carcinoma and the group of low-grade papillary carcinoma(<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0115224#pone-0115224-t001" target="_blank">Table 1</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0115224#pone-0115224-t002" target="_blank">Table 2</a>).</p><p>The associations of attenuated XPF/XPC expression with tumor grade and the patients' smoking status in 219 patients with bladder cancer.</p

Decreased XPF and XPC expression in 79 patients of human bladder cancer.

<p>Decreased XPF and XPC expression in 79 patients of human bladder cancer.</p

The smoking status and bladder cancer recurrence.

<p>Kaplan-Meier Curves using log rank tests for the recurrence of bladder cancer in patients. (a) The recurrence of bladder cancer in XPF(−) group with different status of smoking (never smoked, <20 pack-years, 20-50 pack-years and>50 pack-years); (b) The recurrence of bladder cancer in XPC(−) group with different status of smoking; (c) The recurrence of bladder cancer in XPF(+) group with different status of smoking; (d) The recurrence of bladder cancer in XPC(+) group with different status of smoking; (e) The recurrence of bladder cancer in patients of XPF(−) with never smoked and XPF(−) with smoked more than 50 pack-years;(f) The recurrence of bladder cancer in patients of XPC(−) with never smoked and XPC(−) with smoked more than 50 pack-years;(g) The recurrence of bladder cancer in patients of XPF(+) with never smoked and XPF(+) with smoked more than 50 pack-years; (h) The recurrence of bladder cancer in patients of XPC(+) with never smoked and XPC(+) with smoked more than 50 pack-years.</p